期刊文献+

神经母细胞瘤细胞Boyden小室体外侵袭模型的建立及意义探讨 被引量:3

Establishing Boyden chamber for invasive neuroblastoma
原文传递
导出
摘要 目的 建立神经母细胞瘤细胞Boyden小室体外侵袭模型.对其实验条件、方法 及模型的意义进行探讨.方法 将不同浓度(1.5×105、2.0×105、2.5×105、3.0×105/ml)的100μl 4组神经母细胞瘤细胞系置入Boyden小室侵袭模型上室,分别培养24、36、48、60h,观察不同浓度的细胞在不同时间穿透基质胶聚碳酸酯膜的细胞数,用Boyden小室测定4组神经母细胞瘤细胞系侵袭的能力.结果 Boyden小室侵袭模型显示4组不同细胞系的侵袭能力不完全相同,在第24 h透过ECM胶聚碳酸酯膜的细胞较少,随时间的延长而增多,在48h前后增幅最明显;同时,随细胞浓度的增高,透过细胞数也增加,但细胞浓度大于2.5×105/ml时,透过ECM胶聚碳酸酯膜的细胞数变化不显著;在同一条件下,有骨髓转移能力的细胞系其侵袭能力大于无骨髓转移能力的细胞系.结论 本实验成功建立了神经母细胞瘤细胞Boyden小室体外侵袭模型,该模型对体外神经母细胞瘤细胞侵袭能力的测定和研究及对探明神经母细胞瘤的转移机制和影响因素具有重要意义. Objective To establish a Boyden chamber for invasive human neuroblastoma cell study. Methods We used Boyden chamber in vitro assay to investigate the invasion of four cell lines.100μl four cell suspension of various concentrations (1.5 × 105、 2. 0 × 105 、 2. 5 × 105 、 3. 0 × 105/ml)was added into the upper chamber of the Boyden chamber,and the cells were allowed to penetrate the membrane for 24,36,48 and 60 hours respectively. The invasion rate was assessed by quantifying cells on the under surface of the membrane. Results Boyden chamber invasion models showed that the invasion of four different cell lines was different. The invasive cell quantity was low 24 hours after the incubation, and it increased dramatically at 48 hours. After 48 hours the rate reached a relative plateau. The invasion quantity was high as the cells concentration added increased. The increase slowed down when the cell concentration was above 2. 5 × 105/ml. Under the same conditions, the invasion ability of cells with the capacity of bone marrow metastasis than the cells without ability of bone marrow metastasis.Conclusions We successfully adopted the Boyden chamber for the neuroblastoma cells. It will be crucial for future study of the invasive ability of the neuroblastoma cells.
出处 《中华小儿外科杂志》 CSCD 北大核心 2010年第6期458-462,共5页 Chinese Journal of Pediatric Surgery
关键词 神经母细胞瘤 肿瘤侵润 Neuroblastoma Neoplasm invasiveness
  • 相关文献

参考文献17

二级参考文献40

  • 1高强,董蒨,鹿洪亭,罗兵,吕振华,孙丽荣.神经母细胞瘤体外细胞系的构建方法[J].山东医药,2004,44(21):3-4. 被引量:6
  • 2程瑜,董蒨,孙立荣,杨传民,江布先.基质金属蛋白酶及其抑制因子与神经母细胞瘤侵袭转移的关系[J].中华肿瘤杂志,2005,27(3):164-166. 被引量:14
  • 3颜春洪,韩锐.抗恶性肿瘤转移药的实验研究[J].中华肿瘤杂志,1996,18(6):479-481. 被引量:9
  • 4Grigioni WF, D'Errico A, Forttmato C, et al.Prognosis of gastric carcinoma reversed by interaotions between tumor cells and basement membrance.Mod P athol,1994,7:220-225.
  • 5Monteagudo C,Merino JM,San-Juan J, et al. Immuno-hischemical distribution of collagenases IV in normal ,benign and malignant breast tissues .Am J Pathol,1990,136:585-592.
  • 6D'Errico A, Carbisa S, Loitla LA, et al. Augmentation of collagenase IV,laminin recepter and Ki 62 proliferation antigen associated with human colon,gastric and breast carcinoma progression.Mod Pathol,1991,4:239-246.
  • 7Ara BT, Fukuzawa M,Kusafuka T,et al. Immunohistochemical expression of MMP-2,MMP-9,and TIMP-2 in neuroblastoma:Association with tumor progression and clinical outcome.J Pediatric Surgery , 1998 Aug, 33(8) : 1272-1278.
  • 8Sugiura Y, Shimada H, Robert C, et al. Metrix meeallo-proteinases-2 and -9 are expressed in human neuroblastoma:Contribution of stromal cells to their production and correlation with metastasis.Cancer Research , 1998, 15(58):2209-2216.
  • 9Onisto M,Ricco MP, Scannapieco P, et al. Gelatinaws A/TIMP-2 imbanlance in lymph node positive breast carcinomas, as measured by RT-PCR.Int J Cancer, 1995,63:621-626.
  • 10Onisto M, Garbisa S, Caenazzo C, et al. Reverse transcriptionpolymerase chain reaction phenotyping of metalloproteinases and inhibitors inclued in tumor matrix invasion.Diagn Mol Pathol,1993,2:74-80.

共引文献54

同被引文献33

  • 1鲍镇美.前列腺癌的预防及诊断治疗[J].中华泌尿外科杂志,2004,25(12):797-799. 被引量:9
  • 2郝希伟,董蒨,鹿洪亭,吕振华,孙立荣,江布先.神经母细胞瘤荷瘤鼠模型建立的实验研究[J].中华小儿外科杂志,2005,26(7):372-375. 被引量:16
  • 3余凯远,翁志梁,王思齐,余志贤,陈伟,吴秀玲,李澄棣.间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较[J].中华泌尿外科杂志,2006,27(11):761-764. 被引量:31
  • 4宋华,董蒨,吕振华,侯琳,孙立荣,王伟,鹿洪亭,郝希伟.KAI1/CD82在神经母细胞瘤转移中的表达及意义[J].中华小儿外科杂志,2007,28(8):429-432. 被引量:2
  • 5Dong JT,Isaacs WB,Barrett JC,et al. Genomic organization of the human KAIlmetastasis suppressor gene. Genomies, 1997, 41 (1) :25-29.
  • 6Malik FA, Sanders AJ, Jiang WG. KAI1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol, 2009,24(4) 519-530.
  • 7Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppres- sor. Cancer Lett, 2006,240(2) : 183-194.
  • 8Uzawa K, Ono K, Suzuki H, et al. High prevalence of decreased expression of KAII metastasis suppressor in human oral carci- nogenesis. Clin Cancer Res, 2002,8 (3) : 828-831.
  • 9Bail R, Zhang Y, Zhang F, et al. Transmembrane inter-actions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol,2009,174(2) :647-660.
  • 10Marreirosl A, Dudgeon K, Dao K, et al. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAII expression in cancer ceils. Oncogene, 2005,24 (4) : 637-639.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部